Design, Synthesis and Cytotoxic Evaluation of Novel Imatinib Amide Derivatives that Target Abl Kinase

Author(s): Ri-Sheng Yao, Qiu-Xiang Guan, Xiao-Qin Lu, Ban-Feng Ruan

Journal Name: Letters in Drug Design & Discovery

Volume 12 , Issue 1 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Novel imatinib amide derivatives (a1-28, b1-9) were synthesized and evaluated for their biological activities. All compounds were characterized by 1H NMR, MS and elemental analysis. Among all the derivatives, compounds a4, a10, a21, b1 and b2 displayed the most significant ability of inhibiting K562 cell proliferation with the IC50 values of 0.67, 0.66, 0.65, 0.59 and 0.62 µM, respectively, indicating that these compounds were potent inhibitors of Bcr-Abl in leukemic K562 cells, comparable to the reference compound imatinib. Molecular docking study was performed to position compounds a21 and b1 into the active site of Abl to determine the probable binding modes.

Keywords: Amide derivatives, Bcr-Abl inhibitors, chronic myeloid leukemia, imatinib, inhibiting activity, molecular docking, SAR.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 29 October, 2014
Page: [20 - 28]
Pages: 9
DOI: 10.2174/1570180811666140812231519

Article Metrics

PDF: 54
PRC: 3